REFERENCES Cancer Facts & Figures

REFERENCES
1. American Cancer Society. Cancer Facts & Figures 2007. Atlanta:
American Cancer Society, 2007.
2. World Health Organization. Cancer: Fact Sheet No. 297, February
2006. Available at: http://www.who.int/mediacentre/factsheets/fs297/
en/index.html. Accessed February 14, 2008.
3. Espey DK, Wu XC, Swan J, et al. Annual report to the nation on the
status of cancer, 1975–2004, featuring cancer in American Indians and
Alaska Natives. Cancer 2007;110:2119–2152.
4. Peto R, Darby S, Deo H, et al. Smoking, smoking cessation, and lung
cancer in the UK since 1950: combination of national statistics with
two case-control studies. BMJ 2000;321:323–329.
5. Tong L, Spitz MR, Fueger JJ, et al. Lung carcinoma in former smokers.
Cancer 1996;78:1004–1010.
6. Grover F, Piantadosi S. Recurrence and survival following resection of
bronchioloalveolar carcinoma of the lung—The Lung Cancer Study
Group experience. Ann Surg 1989;209:779–790.
7. van Iersel CA, de Konig HJ, Draisma G, et al. Risk-based selection from
the general population in a screening trial: selection criteria, recruitment
and power for the Dutch-Belgian randomized lung cancer multi-slice
CT screening trial (NELSON). Int J Cancer 2006;120:868–874.
8. Bastarrika G, Pueyo JC, Mulshine JL. Radiologic screening for lung
cancer. Expert Rev Anticancer Ther 2002;2:385–392.
9. Strauss GM, Dominioni L. Perception, paradox, paradigm: Alice in
the wonderland of lung cancer prevention and early detection. Cancer
2000;89:2422–2231.
10. Doll R, Hill A. Smoking and carcinoma of the lung. BMJ 1950:739–748.
11. Wynder EL, Graham EA. Tobacco smoking as a possible etiologic factor
in bronchiogenic carcinoma: a study of 684 proved cases. JAMA
1950;143:329–336.
12. U.S. Department of Health and Human Services. Reducing the health
consequences of smoking: 25 years of progress. A report of the Surgeon
General. In: U.S. Department of Health and Human Services, Centers
for Disease Control and Prevention, National Center for Chronic Disease
Prevention and Health Promotion, Office on Smoking and Health, 1989.
13. American Lung Association. Smoking 101 fact sheet, August 2008.
Available at: http://www.lungusa.org/site/c.dvLUK9O0E/b.39853/.
Accessed September 5, 2009.
14. Centers for Disease Control and Prevention (CDC). Youth Risk Behavior
Surveillance—United States, 2005: Surveillance Summaries, June 9, 2006.
MMWR Morb Mortal Wkly Rep 2006;55(No. SS-5):1–108.
15. U.S. Department of Health and Human Services. The health con sequences
of involuntary exposure to tobacco smoke: a report of the Surgeon
General. Atlanta, GA: U.S. Department of Health and Human Services,
Centers for Disease Control and Prevention, Coordinating Center for
Health Promotion, National Center for Chronic Disease Prevention and
Health Promotion, Office of Smoking and Health, 2006.
16. Centers for Disease Control and Prevention (CDC). Annual smoking-
attributable mortality, years of potential life lost, and productivity
losses—United States, 1997–2001. MMWR Morb Mortal Wkly Rep
2005;54:625–628.
17. American Lung Association. Epidemiology and Statistics Unit. Research
and Program Services. Trends in tobacco use. Washington, D.C.: American
Lung Association, 2007.
18. Centers for Disease Control and Prevention (CDC). Cigarette use
among high school students—United States, 1991–2005. MMWR
Morb Mortal Wkly Rep 2006;55:724–726.
19. World Health Organization. WHO Report on the Global Tobacco
Epidemic, 2008: The MPOWER package. Geneva, World Health
Organization, 2008.
20. Fiore MC, Croyle RT, Curry SJ, et al. Preventing 3 million premature
deaths and helping 5 millions smokers quit: a national action plan for
tobacco cessation. Am J Public Health 2004;94:205–210.
21. Centers for Disease Control and Prevention. Best practices for comprehensive
tobacco control programs—2007. Atlanta: U.S. Department
of Health and Human Services, Centers for Disease Control and
Prevention, National Center for Chronic Disease Prevention and
Health Promotion, Office on Smoking and Health, October 2007.
22. Orleans CT, Cummings KM. Population-based tobacco control: progress
and prospects. Am J Health Promot 1999;14:83–91.
23. Fichtenberg CM, Glantz SA. Youth access interventions do not affect
youth smoking. Pediatrics 2002;109:1088–1092.
24. Koh HK, Judge CM, Robbins H, et al. The first decade of the Massachusetts
Tobacco Control Program. Public Health Rep 2005;120:482–495.
25. Halpern-Felsher BL, Biehl M, Kropp RY, et al. Perceived risks and benefits
of smoking: differences among adolescents with different smoking
experiences and intentions. Prev Med 2004;39:559–567.
26. American Nonsmokers’ Rights Foundation. Overview list: how
many smoke-free laws? Available at: http://www.no-smoke.org/pdf/
mediaordlist.pdf. Updated January 2, 2008. Accessed January 4, 2008.
27. Pickett MS, Schober SE, Brody DJ et al. Smoke-free laws and secondhand
smoke exposure in US non-smoking adults, 1999–2002. Tob
Control 2006;15:302–307.
28. Centers for Disease Control and Prevention. Tobacco use among adults –
United States, 2005. MMWR Morb Mortal Wkly Rep 2006;55:1145–1148.
29. An LC, Zhu SH, Nelson DB et al. Benefits of telephone care over primary
care for smoking cessation: a randomized trial. Arch Intern Med
2006;166:536–542.
30. Cummings KM, Hyland A, Fix B, et al. Free nicotine patch giveaway
program: 12-month follow-up of participants. Am J Prev Med
2006;31:181–184.
31. Curry SJ, Orleans CT, Keller P, et al. Promoting smoking cessation in the
healthcare environment: 10 years later. Am J Prev Med 2006;31:269–272.
32. McPhillips-Tangum C, Rehm B, Carreon R, et al. Addressing tobacco
in managed care: results of the 2003 survey. Prev Chronic Dis (serial
online) 2006 Jul (1/8/08). Available at: http://www.cdc.gov/pcd/issues/
2006/jul/05_0173.htm.
33. Bondi MA, Harris JR, Atkins D, et al. Employer coverage of clinical
preventive services in the United States. Am J Health Promot
2006;20:214–222.
34. Halpin HA, Bellows NM, McMenamin SB. Medicaid coverage for tobacco-
dependence treatments. Health Aff (Millwood) 2006;25:550–556.
35. American Cancer Society. Cancer Prevention & Early Detection Facts &
Figures 2007 . Atlanta: American Cancer Society, 2007.
36. Farrelly MC, Davis KC, Haviland ML, et al. Evidence of a doser
esponse relationship between “truth” antismoking ads and youth
smoking prevalence. Am J Public Health 2005;95:425–431.
37. Ross H, Powell LM, Tauras JA, et al. New evidence on youth smoking
behavior based on experimental price increases. impacTEEN (serial
online) 2003 October (1/8/08). Available at: http://www.impacteen.
org/generalarea_pdfs/ Ross_paperpeerelast101003.pdf.
38. Farrelly, MC, Healton, CG, Davis KC, et al. Getting to the truth:
evaluating national tobacco countermarketing campaigns. Am J Public
Health 2002;92:901–907.
39. Wakefield M, Forster J. Growing evidence for new benefit of clean indoor
air laws: reduced adolescent smoking. Tob Control 2005;14:292–293.
40. Hyland A, Bauer JE, Li Q, et al. Higher cigarette prices influence cigarette
purchase patterns. Tob Control 2005;14:86–92.
41. Hyland A, Higbee C, Li Q, et al. Access to low-taxed cigarettes deters
smoking cessation attempts. Am J Public Health 2005;95:994–995.
42. U.S. Department of Health and Human Services. Reducing tobacco
use: a report of the Surgeon General. Atlanta, GA: U.S. Department of
Health and Human Services, Centers for Disease Control and Prevention,
National Center for Chronic Disease Prevention and Health Promotion,
Office on Smoking and Health, 2000.
43. Godtfredsen NS, Prescott E, Osler M. Effect of smoking reduction on
lung cancer risk. JAMA 2005;294:1505–1510.
44. Lindblom E. Cigarette company price discounts and marketing expenditures
are increasing smoking levels, especially among kids. Available
at: http://www.tobaccofreekids.org/ research/factsheets/pdf/0272.pdf.
Posted May 7, 2007. Accessed November 7, 2007.
45. Frieden TR, Mostashari F, Kerker BD, et al. Adult tobacco use levels
after intensive tobacco control measures: New York City, 2002–2003.
Am J Public Health 2005;95:1016–1023.
46. Centers for Disease Control and Prevention (CDC). Reduced secondhand
smoke exposure after implementation of a comprehensive statewide
ban—New York, June 26, 2003–June 30, 2004. MMWR Morb
Mortal Wkly Rep 2007;56:705–708.
47. Peto R, Darby S, Deo H, et al. Smoking, smoking cessation, and lung
cancer in the UK since 1950: combination of national statistics with
two case-control studies. BMJ 2000;321:323–329.
48. Vineis P, Alavanja M, Buffler P, et al. Tobacco and cancer: recent epidemiological
evidence. J Natl Cancer Inst 2004;96:99–106.
49. Nitadori J, Inoue M, Iwasaki M, et al. Association between lung cancer
incidence and family history of lung cancer: data from a large-scale population-
based cohort study, the JPHC Study. Chest 2006;130:968–975.
50. Tockman MS, Mulshine JL, Piantadosi S, et al. Prospective detection of
preclinical lung cancer: results from two studies of heterogeneous nuclear
ribonucleoprotein A2/B1 overexpression. Clin Cancer Res 1997;3:
2237–2246.
51. Hirsch FR, Franklin WA, Gazdar AF, et al. Early detection of lung cancer:
clinical perspectives of recent advances in biology and radiology.
Clin Cancer Res 2001;7:5–22.
52. Sueoka E, Goto Y, Sueoka N, et al. Heterogeneous nuclear ribonucleoprotein
B1 as a new marker of early detection for human lung cancers.
Cancer Res 1999;59:1404–1407.
53. Mulshine JL, De Luca LM, Dedrick RL, et al. Considerations in developing
successful, population-based molecular screening and prevention
of lung cancer. Cancer 2000;89:2465–2467.
54. Ten Have-Opbroek AA, Benfield JR, Hammond WG, et al. In favour
of an oncofoetal concept of bronchogenic carcinoma development.
Histol Histopathol 1994;9:375–384.
55. Sporn MB, Dunlop NM, Newton DL, et al. Prevention of chemical
carcinogenesis by vitamin A and its synthetic analogs (retinoids). Fed
Proc 1976;35:1332–1338.
56. van Zandwijk N. Chemoprevention in lung carcinogenesis—an overview.
Eur J Cancer 2005;41:1990–2002.
57. Wattenberg LW, Wiedmann TS, Estensen RD, et al. Chemoprevention
of pulmonary carcinogenesis by aerosolized budenoside female A/J
mice. Cancer Res 1997;57:5489–5492.
58. Dahl AR, et al. Inhaled isoretinoin (13-cis retinoic acid) is an effective
lung cancer chemopreventative agent in A/J mice at low doses: a pilot
study. Clin Cancer Res 2000;6:3015–3024.
59. Jordan C. Historical perspective on hormonal therapy of advanced
breast cancer. Clin Ther 2002;24(suppl):A3–A16.
60. Fisher B, Constantino JP, Wickerham DL, et al. Tamoxifen for the prevention
of breast cancer: current status of the national surgical adjuvant breast
and bowel project P-1 study. J Natl Cancer Inst 2005;97:1652–1662.
61. Kelloff GJ, O’Shaughnessy JA, Gordon GB, et al. Counterpoint:
Because some surrogate end point biomarkers measure the neoplastic
process they will have high utility in the development of cancer chemopreventive
agents against sporadic cancers. Cancer Epidemiol Biomarkers
Prev 2003;12:593–596.
62. Toloza EM, Morse MA, Lylerly HK. Gene therapy for lung cancer.
J Cell Biochem 2006;99:1–22.
63. Kelloff GJ, Lippman SM, Dannenberg AJ, et al. Progress in chemopreventioin
drug development: the promise of molecular biomarkers
for prevention of intraepithelial neoplasia and cancer—a plan to move
forward. Clin Cancer Res 2006;12:3661–3697.
64. Keith RL, Miller YE. Lung cancer: genetics of risk and advances in
chemoprevention. Curr Opin Pulm Med 2005;11:265–271.
65. Swanson CA, Mao BL, Li JY, et al. Dietary determinants of lungcancer
risk: results from a case-control study in Yunnan Province,
China. Int J Cancer 1992;50:876–880.
66. Dosil-Díaz O, Ruano-Ravina A, Gestal-Otero JJ, et al. Meat and fish
consumption and risk of lung cancer: a case-control study in Galicia,
Spain. Cancer Lett 2007;252:115–122.
67. Brennan P, Fortes C, Butler J, et al. A multicenter case-control study
of diet and lung cancer among non-smokers. Cancer Causes Control
2000;11:49–58.
68. Galeone C, Negri E, Pelucchi C, et al. Dietary intake of fruit and vegetable
and lung cancer risk: a case-control study in Harbin, northeast
China. Ann Oncol 2007;18:388–392.
69. Nyberg F, Agrenius V, Svartengren K, et al. Dietary factors and risk of
lung cancer in never-smokers. Int J Cancer 1998;78:430–436.
70. Feskanich D, Ziegler RG, Michaud DS, et al. Prospective study of fruit
and vegetable consumption and risk of lung cancer among men and
women. J Natl Cancer Inst 2000;92:1812–1823.
71. Gray J, Mao JT, Szabo E, et al. Lung cancer chemoprevention:
ACCP evidence-based clinical practice guidelines (2nd edition). Chest
2007;132:S56–S68.
72. Kamangar F, Qiao YL, Yu B, et al. Lung cancer chemoprevention: a
randomized, double-blind trial in Linxian, China. Cancer Epidemiol
Biomarkers Prev 2006;15:1562–1564.
73. Akhmedkhanov A, Toniolo P, Zeleniuch-Jacquotte A, et al. Aspirin and
lung cancer in women. Br J Cancer 2002;87:49–53.
74. Harris RE, Beebe-Donk J, Schuller HM. Chemoprevention of lung
cancer by non-steroidal anti-inflammatory drugs among cigarette
smokers. Oncol Rep 2002;9:693–695.
75. Moysich KB, Menezes RJ, Ronsani A, et al. Regular aspirin use and
lung cancer risk. BMC Cancer 2002;2:31.
76. Schreinemachers DM, Everson RB. Aspirin use and lung, colon, and breast
cancer incidence in a prospective study. Epidemiology 1994;5:138–146.
77. Cook NR, Lee IM, Gaziano JM, et al. Low-dose aspirin in the primary
prevention of cancer: the Women’s Health Study: a randomized controlled
trial. JAMA 2005;294:47–55.
78. Friis S, Sørensen HT, McLaughlin JK, et al. A population-based cohort
study of the risk of colorectal and other cancers among users of lowdose
aspirin. Br J Cancer 2003;88:684–688.
79. Holick CN, Michaud DS, Leitzmann MF, et al. Aspirin use and lung
cancer in men. Br J Cancer 2003;89:1705–1708.
80. Paganini-Hill A, Chao A, Ross RK, et al. Aspirin use and chronic diseases:
a cohort study of the elderly. BMJ 1989;299:1247–1250.
81. Peto R, Gray R, Collins R, et al. Randomised trial of prophylactic
daily aspirin in British male doctors. Br Med J (Clin Res Ed) 1988;296:
313–316.
82. Feskanich D, Bain C, Chan AT, et al. Aspirin and lung cancer risk in
a cohort study of women: dosage, duration and latency. Br J Cancer
2007;97:1295–1299.
83. Muscat JE, Chen SQ, Richie JP Jr, et al. Risk of lung carcinoma among
users of nonsteroidal antiinflammatory drugs. Cancer 2003;97:1732–1736.
84. Hernández-Diaz S, García Rodriguez LA. Nonsteroidal anti-i nflammatory
drugs and risk of lung cancer. Int J Cancer 2007;120:1565–1572.
85. Skriver MV, Norgaard M, Poulsen AH, et al. Use of nonaspirin NSAIDs
and risk of lung cancer. Int J Cancer 2005;117:873–876.
86. Wall RJ, Shyr Y, Smalley W. Nonsteroidal anti-inflammatory drugs and
lung cancer risk: a population-based case control study. J Thorac Oncol
2007;2:109–114.
87. Tanaka T, Delong PA, Amin K, et al. Treatment of lung cancer using
clinically relevant oral doses of the cyclooxygenase-2 inhibitor rofecoxib:
potential value as adjuvant therapy after surgery. Ann Surg
2005;241:168–178.
88. Rioux N, Castonguay A. Prevention of NNK-induced lung tumorigenesis
in A/J mice by acetylsalicylic acid and NS-398. Cancer Res
1998;58:5354–5360.
89. Keith RL, Miller YE, Hudish TM, et al. Pulmonary prostacyclin synthase
overexpression chemoprevents tobacco smoke lung carcinogenesis
in mice. Cancer Res 2004;64:5897–5904.
90. Masferrer JL, Leahy KM, Koki AT, et al. Antiangiogenic and antitumor
activities of cyclooxygenase-2 inhibitors. Cancer Res 2000;
60:1306–1311.
91. Mao JT, Tsu IH, Dubinett SM, et al. Modulation of pulmonary leukotriene
B4 production by cyclooxygenase-2 inhibitors and lipopolysaccharide.
Clin Cancer Res 2004;10:6872–6878.
92. Mao JT, Fishbein MC, Adams B, et al. Celecoxib decreases Ki-67 proliferative
index in active smokers. Clin Cancer Res 2006;12:314–320.
93. Khurana V, Bejjanki HR, Caldito G, et al. Statins reduce the risk of
lung cancer in humans: a large case-control study of US veterans. Chest
2007;131:1282–1288.
94. Omenn GS, Goodman GE, Thornquist MD, et al. Effects of a combination
of beta carotene and vitamin A on lung cancer and cardiovascular
disease. N Engl J Med 1996;334:1150–1155.
95. The Alpha-Tocopherol, Beta Carotene Cancer Prevention Study Group.
The effect of vitamin E and beta carotene on the incidence of lung cancer
and other cancers in male smokers. N Engl J Med 1994;330:1029–1035.
96. Lee IM, Cook NR, Manson JE, et al. Beta-carotene supplementation
and incidence of cancer and cardiovascular disease: the women’s health
study. J Natl Cancer Inst. 1999;91:2102–2106.
97. Yankelevitz DF, Reeves AP, Kostis WJ, et al. Small pulmonary nodules:
volumetrically determined growth rates based on CT evaluation.
Radiology 2000;217:251–256.
98. Hong WK, Lippman SM, Itri LM, et al. Prevention of second primary
tumors with isotretinoin in squamous-cell carcinoma of the head and
neck. N Engl J Med 1990;323:795–801.
99. Pastorino U, Infante M, Maioli M, et al. Adjuvant treatment of stage I
lung cancer with high-dose vitamin. J Clin Oncol 1993;11:1216–1222.
100. Mulshine JL, De Luca LM. Lung cancer chemoprevention: an opportunity
for direct delivery. In: Kelloff GJ, Hawk ET, Sigman CC, eds.
Cancer Chemoprevention Vol. 2: Strategies for Cancer Chemoprevention .
2nd ed. New Jersey: Human Press, 2005.
101. Lippman SM, Lee JJ, Karp DD, et al. Randomized phase III intergroup
trial of isotretinoin to prevent second primary tumors in stage I
non-small-cell lung cancer. J Natl Cancer Inst 2001;93:605–618.
102. van Zandwijk N, Dalesio O, Pastorino U, et al. EUROSCAN, a randomized
trial of vitamin A and N-acetylcysteine in patients with head
and neck cancer or lung cancer. For the European Organization for
Research and Treatment of Cancer Head and Neck and Lung Cancer
Cooperative Groups. J Natl Cancer Inst 2000;92:977–986.
103. Hong WK, Endicott J, Itri LM, et al. 13-cis-retinoic acid in the treatment
of oral leukoplakia. N Engl J Med 1986;315:1501–1505.
104. Kohlhäufl M, Häussinger K, Stanzel F, et al. Inhalation of aerosolized
vitamin A: reversibility of metaplasia and dysplasia of human respiratory
epithelia — a prospective pilot study. Eur J Med Res 2002;7:72–78.
105. Lee IM, Cook NR, Gaziano JM, et al. Vitamin E in the primary prevention
of cardiovascular disease and cancer: the women’s health study;
a randomized controlled trial. JAMA 2005;294:56–65.
106. Hennekens CH, Buring JE, Manson JE, et al. Lack of effect of long-term
supplementation with beta carotene on the incidence of malignant neoplasms
and cardiovascular disease. N Engl J Med 1996;334:1145–1149.
107. Lam S, leRiche JC, McWilliams A, et al. A randomized phase IIb trial
of pulmicort turbuhaler (budesonide) in people with dysplasia of the
bronchial epithelium. Clin Cancer Res 2004;10:6502–6511.
108. van den Berg RM, Teertstra HJ, van Zandwijk N, et al. CT detected
indeterminate pulmonary nodules in a chemoprevention trial of fluticasone.
Lung Cancer 2008;60:57–61.
109. van den Berg RM, van Tinteren H, van Zandwijk N, et al. The influence
of fluticasone inhalation on markers of carcinogenesis in bronchial
epithelium. Am J Respir Crit Care Med 2007;175:1061–1065.
110. Parimon T, Chien JW, Bryson CL, et al. Inhaled corticosteroids and
risk of lung cancer among patients with chronic obstructive pulmonary
disease. Am J Respir Crit Care Med 2007;175:712–719.
111. Reid ME, Duffield-Lilico AJ, Garland L, et al. Selenium supplementation
and lung cancer incidence: an update of the nutritional prevention
of cancer trial. Cancer Epidemiol Biomarkers Prev 2002;11;1285–1291.
112. Omenn GS. Chemoprevention of lung cancers: lessons from CARET,
the beta-carotene and retinol efficacy trial, and prospects for the future.
Eur J Cancer Prevention 2007;16:184–191.
113. Hirsch FR, Lippman SM. Advances in the biology of lung cancer chemoprevention.
J Clin Oncol 2005;23:3186–3197.
114. Wardwell NR, Massion PP. Novel strategies for the early detection and
prevention of lung cancer. Semin Oncol 2005;32:259–268.
115. Veronesi U, Bonanni B. Chemoprevention: from research to clinical
oncology. Eur J Cancer 2005;41:1833–1841.
116. Henschke C, Yankelevitz D, Libby D, et al. Survival of patients with
stage I lung cancer detected on CT screening. N Engl J Med 2006;
355:1763–1771.
117. SEER cancer statistics review, 1975–2003. National Cancer Institute,
2006. Available at: http://seer.cancer.gov/csr/1975_2003/results_
merged/topic_lifetime_risk.pdf. Accessed November 21, 2006 .
118. Humphrey LL, Teutsch S, Johnson M. Lung cancer screening with
sputum cytological examination, chest radiography and computed tomography:
an update for the U.S. Preventive Services Task Force. Ann
Intern Med 2004;140:740–753.
119. Henschke C, Yankelevitz D, Libby D, et al. Survival of patients with
stage I lung cancer detected on CT screening. N Engl J Med 2006;
355:1763–1771.
120. Swensen SJ, Jett JR, Hartman TE, et al. CT screening for lung cancer:
five-year prospective experience. Radiology 2005;235:259–265.
121. Gould MK, Fletcher J, Iannettoni MD, et al. American College of
Chest Physicians. Evaluation of patients with pulmonary nodules:
when is it lung cancer?: ACCP evidence-based clinical practice guidelines
(2nd edition). Chest 2007;132:108–130S.
122. Veronesi G, Bellomi M, Veronesi U, et al. Role of positron e mission
tomography scanning in the management of lung nodules d etected at
baseline computed tomography screening. Ann Thorac Surg 2007;84:
959–965.
123. Asamura H, Suzuki K, Watanabe S, et al. A clinicopathological study of
resected subcentimeter lung cancers: a favorable prognosis for ground
glass opacity lesions. Ann Thorac Surg 2003;76:1016–1022.
124. Henschke CI, McCauley DI, Yankelevitz DF, et al. Early lung cancer
action project: overall design and findings from baseline screening.
Lancet 1999;354:99–105.
125. McKenna RJ, Houck W, Fuller CB. Video-assisted thoracic surgery
l obectomy: experience with 1100 cases. Ann Thorac Surg 2006;81:
421–426.
126. Allen MS, Darling GE, Pechet TT, et al. Morbidity and mortality of
major pulmonary resections in patients with early-stage lung cancer:
initial results of the randomized prospective ACOSOG Z0030 trial.
Ann Thorac Surg 2006;81;1013–1020.
127. Ginsberg RJ, Rubinstein LV. Randomized trial of lobectomy versus
limited resection for T1 N0 non-small cell lung cancer. Lung Cancer
Study Group. Ann Thorac Surg 1995;60:615–622.
128. Asamura H, Goya T, Koshiishi Y, et al. How should the TNM staging system
for lung cancer be revised? A simulation based on the Japanese Lung
Cancer Registry populations. J Thorac Cardiovasc Surg 2006;132:316–319.
129. Nakamura H, Kawasaki N, Taguchi M, et al. Survival following lobectomy
vs limited resection for stage I lung cancer: a meta-analysis. Br J
Cancer 2005;28;92:1033–1037.
130. Nakayama H, Yamada K, Saito H, et al. Sublobar resection for patients
with peripheral small adenocarcinomas of the lung: surgical outcome
is associated with features on computed tomographic imaging. Ann
Thorac Surg 2007;84:1675–1679.
131. National Cancer Institute, Clinical Trials. Phase III Randomized
Study of Lobectomy Versus Sublobar Resection in Patients with Small
Peripheral Stage IA Non-Small Cell Lung Cancer. Available at: http://
www.cancer.gov/clinicaltrials/CALGB-140503.
132. Pennathur A, Luketich JD, Abbas G, et al. Radiofrequency ablation for
the treatment of stage I non-small cell lung cancer in high-risk patients.
J Thorac Cardiovasc Surg 2007;134:857–864.
133. Dupuy DE, DiPetrillo T, Gandhi S, et al. Radiofrequency ablation followed
by conventional radiotherapy for medically inoperable stage I
non-small cell lung cancer. Chest 2006;129:738–745.
134. Simon CJ, Dupuy DE, DiPetrillo TA, et al. Pulmonary radiofrequency
ablation: long-term safety and efficacy in 153 patients. Radiology
2007;243:268–275.
135. Henschke CI, Yankelevitz DF, Altorki NK. The role of CT screening
for lung cancer. Thorac Surg Clin 2007;17:137–142.
136. Raz DJ, Zell JA, Ou SH, et al. Natural history of stage I nonsmall
cell lung cancer: implications for early detection. Chest
2007;132:193–199.
137. Parkin DM, Moss SM. Lung cancer screening. Improved survival
but no reduction in deaths–the role of “overdiagnosis.” Cancer
2000;89:2369–2376.
138. Hamashima C, Sobue T, Muramatsu Y, et al. Comparison of observed
and expected numbers of detected cancers in the research
center for cancer prevention and screening program. Jpn J Clin Oncol
2006;36:301–308.
139. McMahon PM, Kong CY, Johnson BE, et al. Estimating long-term
effectiveness of lung cancer screening in the Mayo CT screening study.
Radiology 2008;248:278–287.
140. Chien CR, Chen TH. Mean sojourn time and effectiveness of mortality
reduction for lung cancer screening with computed tomography.
Epidemiology 2008;122(11):2594–2599.
141. Daniel JC, Smythe WR. Gene therapy of lung cancer. Semin Surg
Oncol 2003;21:196–204.
142. Chorostowska-Wynimko J, Szpechcinski A. The impact of genetic
markers on the diagnosis of lung cancer: a current perspective. J Thorac
Oncol 2007;2:1044–1051.
143. Kelloff GJ, Lippman SM, Dannenberg AJ, et al. AACR Task Force on
Cancer Prevention. Progress in chemoprevention drug development:
the promise of molecular biomarkers for prevention of intraepithelial
neoplasia and cancer—a plan to move forward. Clin Cancer Res
2006;12:3661–3697.
144. Gadgeel SM, Ali S, Philip PA, et al. Response to dual blockade of
epidermal growth factor receptor (EGFR) and cycloxygenase-2 in nonsmall
cell lung cancer may be dependent on the EGFR mutational status
of the tumor. Cancer 2007;110:2775–2784.
145. Lippman SM, Gibson N, Subbaramaiah K, et al. Combined targeting
of the epidermal growth factor receptor and cyclooxygenase-2 pathways.
Clin Cancer Res 2005;11:6097–6099.
146. Greenberg AK, Lee MS. Biomarkers for lung cancer: clinical uses. Curr
Opin Pulm Med 2007;13:249–255.